Epigentic enzymes histone deacetylases (HDACs) catalyze the removal of acetyl groups
from the ε-N-acetylated lysine residues of various protein substrates including both histone …

Because the overexpression of histone deacetylase enzymes (HDACs) has been linked to
numerous diseases, including various cancers and neurodegenerative disorders, HDAC …

Histone deacetylases (HDACs) catalyze the hydrolysis of acetyl-l-lysine side chains in
histones and non-histones, which are key to epigenetic regulation in humans. Targeting …

Histone deacetylase 6 (HDAC6) has been targeted in clinical studies for anticancer effects
due to its role in oncogenic transformation and metastasis. Through a second-generation …

Histone deacetylases (HDACs) are a family of 18 epigenetic modifiers that fall into 4 classes.
Histone deacetylase inhibitors (HDACi) are valid tools to assess HDAC functions. HDAC6 …

T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive neoplasm of mature T-cells.
Most patients with T-PLL present with lymphocytosis, anemia, thrombocytopenia, and …

Histone deacetylases (HDACs) have emerged as powerful epigenetic modifiers of
histone/non-histone proteins via catalyzing the deacetylation of ε-N-acetyl lysines. The …

The development of histone deacetylase (HDAC) inhibitors for treating hematologic
malignancies has been widely investigated, while their role in hepatocellular carcinoma …

Pharmacological inhibition of PI3Kδ for battling solid tumors is relatively unexplored. Given
the potential synergism of concurrent PI3Kδ/HDAC6 inhibition, and the drawbacks of …

Abstract Histone deacetylase 6 (HDAC6) induces the expression of pro-inflammatory
cytokines in macrophages; therefore, HDAC inhibitors may be beneficial for the treatment of …